We describe the expression and consistent production of a first target-specific recombinant human polyclonal antibody. An anti-Rhesus D recombinant polyclonal antibody, Sym001, comprised of 25 unique human IgG1 antibodies, was produced by the novel Sympress expression technology. This strategy is based on site-specific integration of antibody genes in CHO cells, using the FRT/Flp-In recombinase system. This allows integration of the expression construct at the same genomic site in the host cells, thereby reducing genomic position effects. Different bioreactor batches of Sym001 displayed highly consistent manufacturing yield, antibody composition, binding potency, and functional activity. The results demonstrate that diverse recombinant human polyclonal antibody compositions can be reproducibly generated under conditions directly applicable to industrial manufacturing settings and present a first recombinant polyclonal antibody which could be used for treatment of hemolytic disease of the newborn and/or idiopathic thrombocytopenic purpura.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bit.20865 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Selection of Candidate Monoclonal Antibodies for the Detection of Clostridium botulinum Neurotoxin Serotype B Light Chain.
Protein Expr Purif
January 2025
Institute of Tropical Medicine, Joint Vietnam-Russia Tropical Science and Technology Research Center.
Botulinum neurotoxin, produced by the bacterium Clostridium botulinum, causes botulism, a severe, rapidly progressing, and potentially fatal condition. Swift detection of the toxin and timely administration of antitoxin antibodies are critical for effective treatment. The current standard for Botulinum toxin testing is the mouse lethality assay, but this method is time-consuming and requires live animals.
View Article and Find Full Text PDFDisposable and sensitive electrochemical magneto-immunosensor for point-of-care HCV diagnostics: Targeting HCVcAg, the active viremia biomarker, in patient samples.
Biosens Bioelectron
December 2024
Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, United Kingdom. Electronic address:
Early detection of hepatitis C virus (HCV) infection is crucial for eliminating this silent killer, especially in resource-limited settings. HCV core antigen (HCVcAg) represents a promising alternative to the current "gold standard" HCV RNA assays as an active viremia biomarker. Herein, a highly sensitive electrochemical magneto-immunosensor for the HCVcAg was developed.
View Article and Find Full Text PDFAn integrated magnetoimpedance biosensor microfluidic magnetic platform for the evaluation of the cardiac marker cTnI.
Anal Methods
January 2025
Microelectronic Research & Development Center, School of Mechatronics Engineering and Automation, Shanghai University, Shanghai 200444, China.
An integrated magnetoimpedance (MI) biosensor microfluidic magnetic platform was proposed for the evaluation of the cardiac marker, cardiac troponin I (cTnI). This bioanalyte evaluation platform mainly comprised three external permanent magnets (PMs), one MI element, two peelable SiO film units and a microfluidic chip (MFC). The MI element was made of micro-electro-mechanical system (MEMS)-based multilayered [Ti (6 nm)/FeNi (100 nm)]/Cu (400 nm)/[Ti (6 nm)/FeNi (100 nm)] thin films and designed as meander structures with closed magnetic flux.
View Article and Find Full Text PDFTetraspanin CD81 serves as a functional entry factor for porcine circovirus type 2 infection.
J Virol
December 2024
Key Laboratory of Animal Disease Diagnostics and Immunology, Ministry of Agriculture, MOE International Joint Collaborative Research Laboratory for Animal Health & Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu, China.
Porcine circovirus type 2 (PCV2) is the primary causative agent of porcine circovirus-associated disease, clinically resulting in immunosuppression and co-infections with other pathogens in infected pigs. The mechanism of PCV2 infection remains unclear. In this study, we firstly found that the tetraspanin CD81 in PK-15 cells interacts with PCV2 Cap protein by using virus overlay protein-binding assay combined with mass spectrometry.
View Article and Find Full Text PDFDevelopment and assessment of a novel magnetic nanoparticle antibody-conjugate and aptamer-based assay (MNp-Ab-Ap assay) for the rapid diagnosis of pleural tuberculosis.
Nanotheranostics
January 2025
Translational Research Laboratory, Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Article Synopsis
- Pleural tuberculosis (pTB) is hard to diagnose due to vague symptoms and limited testing options, prompting the development of a new assay using magnetic nanoparticles and antibodies to detect specific antigens related to the disease.
- The MNp-Ab-Ap assay was created by attaching antibodies to magnetic nanoparticles, enabling the capture of pTB antigens from pleural fluid, which were then identified using specialized aptamers.
- In testing, the MPT51-based variant of the assay showed a sensitivity of 66.6% and a high specificity of 95.4%, proving to be more effective than existing methods like the Xpert MTB/RIF test, suggesting it could significantly improve pTB diagnosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!